NASHVILLE, Tenn.--(BUSINESS WIRE)--EvidenceCare, a Nashville-based clinical decision support tool for healthcare providers, is closing the company’s $2 Million Convertible Note B offering this month, bringing the total raised over the last two years to more than $3 Million. This round was initially brought about by existing participants requesting to expand their current investment. Initiated in early January, it also provided the opportunity for new investors to become involved in the company’s early success. Like the previous round, this round was capped off with an additional investment from NueCura Partners, LLC.
“This round of funding is allowing us to accelerate the development of our enterprise offering, which is built for hospitals,” noted EvidenceCare’s COO Jim Jamieson. “As an agile start-up, we are positioned to respond to market demands,” continued Jamieson. “The early favorable reception from physicians for our product has pushed us to expedite our investment in integration with EHRs to make EvidenceCare even more compelling for Enterprise customers.” Originally planned for early 2018, the company will be launching its Enterprise version of EvidenceCare to hospitals this summer.
EvidenceCare’s decision support tool enhances provider workflow and propels the patient-provider relationship by delivering the latest medical content in a manner that is quickly and easily consumable by clinicians at the bedside. The company works with industry leading experts and medical societies to create content in some of the most complex and costly conditions in healthcare.
EvidenceCare was conceived in 2014 to solve a fundamental need for healthcare providers to find and quickly digest the latest treatment guidelines. The company’s patent-pending technology was pioneered by Dr. Brian Fengler, an emergency room physician, and offers a unique dashboard interface that presents evidence based on the unique factors of the specific patient being treated.
“Only 20 percent of US-based healthcare decisions made are evidence-based, which leads to a third of the more than $3.2 Trillion in healthcare expenditures each year being wasted on wrong or inappropriate care,” says Brian Fengler, MD and Chief Executive Officer of EvidenceCare. “It’s time to enhance the patient-provider experience by giving providers a better tool for treating patients that can improve patient outcomes and decrease financial impact for hospitals.”
In addition to investors who span the healthcare landscape, EvidenceCare has amassed advisors who shape and influence organizations on a national and global level. The company’s Advisory Board is comprised of world-renowned economist Dr. Art Laffer, Eric Mueller, who is Chief Healthcare Strategist for Microsoft, and Mary Mirabelli, Vice President of Hewlett Packard Enterprise’s (HPE) Global Healthcare Practice. The board’s role is to provide insight, vision, and expertise on a macro level for the organization. NueCura Founder and Managing Partner, Don Lazas, MD, is a member of EvidenceCare’s Board of Directors.
The company is currently entertaining a Series A equity round of funding targeted for this summer. That round will allow the organization to turn their focus exclusively to rapidly expanding content and the anticipated growth related to the addition of the Enterprise product offering.
Nashville-based EvidenceCare is a clinical decision support platform designed by practicing emergency physician, Dr. Brian Fengler. Unlike any tool on the market, EvidenceCare provides clinicians with access patient specific evidence-based treatment recommendations at the bedside in as little as 30 seconds. Since its launch in July 2016, the company’s proprietary content publishing platform is delivering protocols authored by industry-leading experts to nearly 1800 providers worldwide.
To learn more visit www.evidence.care.